Drugs / GMA161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00244257 | Aug 2005 → Jul 2008 | autoimmune thrombocytopenic purpura | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMA161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00244257 ↗ |
| Known as | HUMANIZED, AGLYCOSYL ANTIBODY, GMA161 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297961 ↗ |
| Route | Intravenous | “0.1 mg/kg, IV infusion on Day 0” NCT00244257 ↗ |